The goal of this clinical trial is to evaluate the influence of parasympathetic transmission from the brain to different metabolic organs. This transmission can be blocked with the muscarinic antagonist atropine.
Participants will undergo an oral glucose tolerance test combined with a double tracer dilution technique either with atropine infusion or placebo.
Healthy individuals and high-risk individuals will be compared to identify possible changes in signaling in high-risk groups. In addition, men and women will be included to take into account possible sex differences.
Protocol Amendment History
4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-03-28; most recent amendment 2025-07-04.
Status change: Not Yet Recruiting → Recruiting2025-05-15